Kisspeptin-10

Kisspeptin-10 pairs a first-rate, mechanistically elegant research program with a thin direct data set for the exact form people buy and impractical kinetics. If you are a curious researcher, or you are in a supervised fertility setting, it is a genuinely interesting upstream switch for the reproductive axis with real Phase 2 efficacy as an OHSS-sparing IVF trigger and real early signals in sexual desire. If you are a casual buyer chasing libido or a post-cycle restart with a single subcutaneous shot, the picture is weaker: the strongest data used kisspeptin-54, the kisspeptin-10 studies used infusion, and the minutes-long half-life makes home dosing poorly aligned with the evidence. It remains investigational and grey-market, so most people seeking the libido use are better served by an approved option.

✅ Best for: Curious researchers who want to understand the master upstream switch of the reproductive axis and will judge it on the academic record rather than marketing. Supervised fertility settings where the OHSS-sparing trigger evidence applies, since that is where the strongest data live. Men with central, under-driven hypogonadism where upstream stimulation has direct proof-of-concept support. People with low sexual desire who understand the trial signals are early and used kisspeptin-54, and who will track their own response. Anyone who can source verified material and accept that this is investigational, not proven.

❌ Avoid if: You are pregnant, breastfeeding, or trying to conceive naturally outside a supervised clinic, since there are no safety data. You have any active or hormone-sensitive cancer, or a reproductive-cancer history, because reproductive-axis stimulation is an obvious caution zone with no data. You expect a single under-the-skin shot to reproduce the trial effects, because the minutes-long half-life means it will not. You plan continuous, more-is-better dosing, which can downregulate the axis and suppress your hormones. You cannot verify your source, since grey-market research-chemical purity and identity are unverified and contamination can exceed the intrinsic peptide risk.